Eficacia del tratamiento con leflunomida en pacientes con artritis psoriásica

In conclusion, the TOPAS and OSPAL clinical trials indicate that LFN is an efficacious and first-line therapeutic option for the treatment of PsA, providing therapeutic benefits for rheumatic symptoms and positive effects on dactylitis and cutaneous symptoms.